X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

How much do you know about Medicare Part B?

By Nicole Longo  |    July 31, 2018
In recent months, the Administration has proposed a number of changes to Medicare Part B. From the Department of Health and Human Services’ request for information, HHS Blueprint To Lower Drug...   Read More

ICER’s budget impact threshold: Sounding a false alarm on affordability and access

By Randy Burkholder  |    July 24, 2018
If a home inspector found “wide and unpredictable variation” in your smoke detectors, would you want to fix them?   Read More

PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs

By Holly Campbell  |    July 16, 2018
Today, PhRMA submitted comprehensive comments to the Department of Health and Human Services (HHS) request for information (RFI), HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs....   Read More

Event next week: Supporting the next generation of lifesaving medicines

By Andrew Powaleny  |    July 12, 2018
The remarkable scientific advancements in recent history are due, in part, to thoughtful public policies that promote innovation and discovery. These policies support the tireless efforts of more...   Read More

Guest post: Excellent care for LGBTQ patients requires cultural humility and specific medical knowledge

By Guest Contributor  |    June 28, 2018
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

New analysis shows that more medicines worldwide are available to U.S. patients

By Kevin Haninger  |    June 5, 2018
In the past year, we have seen revolutionary new treatments become available to patients in the United States for cancer and other debilitating diseases. A new analysis puts in perspective the...   Read More

New analysis shows that HTA organizations may frequently restrict access to cancer treatments

By Randy Burkholder  |    June 1, 2018
In health care, who should decide value? In many industrialized countries with single-payer health systems, the answer is “the government.” A new analysis by Avalere illustrates the negative...   Read More

New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B

By Lauren Neves  |    May 31, 2018
Amidst debate about rising health care costs, some policy-makers have expressed renewed interest in using cost-effectiveness thresholds as the basis for setting coverage and payment policy. But a ...   Read More

Event tomorrow: Improving patient access to lifesaving medicines

By Andrew Powaleny  |    May 22, 2018
Despite the current unprecedented pace of biopharmaceutical innovation, patients continue to face rising out-of-pocket costs and other barriers to care. Tomorrow, in partnership with The Atlantic,...   Read More

Event tomorrow: Making the biopharmaceutical supply chain work for patients

By Katie Koziara  |    May 2, 2018
In the U.S. health care system, the complex process of delivering medicines to patients is highly intermediated and involves many entities, including insurance companies, pharmacy benefit managers...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates